-
Sector Analysis
Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Myasthenia Gravis market through 2034. For the treatment of MG, most patients will be prescribed either corticosteroids or acetylcholinesterase inhibitors, with the corticosteroid prednisone and the acetylcholinesterase inhibitor pyridostigmine being the treatments most prescribed by physicians. When standard treatments fail, monoclonal antibodies are prescribed, offering more targeted, aggressive therapy. The MG market across the 7MM was valued at $6.1 billion in 2024 and is expected to grow...
-
Product Insights
Myasthenia Gravis - Drugs In Development, 2024
Empower your strategies with our Myasthenia Gravis – Drugs In Development, 2024 report and make more profitable business decisions. Myasthenia gravis is an autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia, and difficulty swallowing, chewing, and speaking. Treatment includes immunosuppressants, corticosteroids, and surgery. The Myasthenia Gravis drugs in development market research report provide comprehensive information on the therapeutics under development for Myasthenia Gravis,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.